Glatiramer Acetate

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2587 publications

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Journal: Neurology

Published: April 06, 2026

Genetic Influences on Disease-Modifying Therapy Response in Multiple Sclerosis: Current Insights and Future Directions.

Genetic Influences on Disease-Modifying Therapy Response in Multiple Sclerosis: Current Insights and Future Directions.

Journal: Balkan medical journal

Published: April 01, 2026

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 03, 2026

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 18, 2026

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Journal: Journal of clinical medicine

Published: February 01, 2026

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real-World Clinical Data.

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real-World Clinical Data.

Journal: Brain and behavior

Published: January 05, 2026

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.

Journal: Multiple sclerosis and related disorders

Published: December 20, 2025

Glatiramer acetate stimulates phagocytosis and intracellular killing of Escherichia coli by macrophages and microglial cells.

Glatiramer acetate stimulates phagocytosis and intracellular killing of Escherichia coli by macrophages and microglial cells.

Journal: Frontiers in immunology

Published: December 05, 2025

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Journal: medRxiv : the preprint server for health sciences

Published: November 26, 2025

Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region

Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: November 19, 2025

Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths.

Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths.

Journal: International journal of pharmaceutics

Published: November 13, 2025

Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.

Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: November 04, 2025

Showing 1-12 of 2,587

Last Updated: 04/28/2026